romidepsin
Selected indexed studies
- Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. (Nat Med, 2024) [PMID:38886623]
- Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). (J Clin Oncol, 2022) [PMID:34843406]
- Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. (Blood, 2021) [PMID:33171487]
_Worker-drafted node — pending editorial review._
Connections
romidepsin is a side effect of
Sources
- Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. (2024) pubmed
- Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). (2022) pubmed
- Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. (2021) pubmed
- Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy. (2021) pubmed
- Romidepsin Treatment in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review and Meta-Analysis. (2022) pubmed
- Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. (2024) pubmed
- Romidepsin for peripheral T-cell lymphoma. (2013) pubmed
- Romidepsin for the treatment of non-Hodgkin's lymphoma. (2015) pubmed
- Romidepsin antagonism with CHOEP. (2023) pubmed
- The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active. (2025) pubmed